Recombinant IL-6R (Tocilizumab Biosimilar) antibody
Quick Overview for Recombinant IL-6R (Tocilizumab Biosimilar) antibody (ABIN7795095)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Tocilizumab Biosimilar, Human IL-6R Monoclonal Antibody
-
Characteristics
- What is tocilizumab biosimilar research grade? Tocilizumab biosimilar uses the same protein sequences as the therapeutic antibody tocilizumab. Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by cells including T-cells, B-cells, lymphocytes, monocytes, fibroblasts. IL-6 rapidly induces C-reactive protein, serum amyloid A, fibrinogen, haptoglobin, and α-1-antichymotrypsin while inhibiting production of fibronectin, albumin, and transferrin. IL-6 also induces antibody production, induces cytotoxic T-cell differentiation, and inhibits regulatory T-cell differentiation. Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation.
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human IL-6R
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- IL-6R (Tocilizumab Biosimilar)
-
Alternative Name
- Tocilizumab Biosimilar
-
Target Type
- Biosimilar
Target
-